Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for suggestions, recommendations and comments relevant to the FDA’s newly established Opioid Policy Steering Committee (OPSC) as published in the Federal Register on September 29, 2017.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide information on the application of value-based contracts (VBCs) for insulin pricing initiatives. The shift in payment models is expanding beyond the delivery of health care services to encompass models of compensation between payers and biopharmaceutical manufacturers.
The Academy of Managed Care Pharmacy (AMCP) thanks the Federal Trade Commission (FTC) for the opportunity to provide comments in response to the request for comments titled “Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics” released on October 18, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the proposed rule Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2019 (CMS-9930-P).
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for information titled “Content of Risk Information in the Major Statement in Prescription Drug Direct-to-Consumer Broadcast Advertisements [Docket No. FDA-2017-N-2936]” as published in the Federal Register on August 21, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS), the Centers for Medicare and Medicaid Services (CMS), and the Center for Medicare and Medicaid Innovation (CMMI) for the opportunity to provide comments in response to the request for information (RFI) titled “Centers for Medicare & Medicaid Services: Innovation Center New Direction” released on September 20, 2017.
Our organizations view medication-assisted treatment (MAT) as an important component of a multipronged approach to addressing opioid abuse and improving treatment. We applaud efforts to expand access to MAT, such as increasing Drug Addiction Treatment Act (DATA) waivered physician’s prescribing caps and allowing nurse practitioners (NPs) and physician assistants (PAs) to obtain a DATA waiver.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide input into the Texas Board of Pharmacy’s (Board) strategic planning process for fiscal years 2019-2023. As the profession of pharmacy continues to evolve and the role of pharmacists expand from dispensers of medications to direct care providers, so too must Board requirements.
The Academy of Managed Care Pharmacy (AMCP) thanks the Arkansas State Board of Pharmacy (Board) for the opportunity to provide comments on the proposed changes to Regulation 7 – Drug Products/Prescriptions as they relate to biosimilar products.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for comments titled “Administering the HatchWaxman Amendments: Ensuring a Balance Between Innovation and Access [Docket No. FDA–2017–N–3615]” as published in the Federal Register on June 22, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the solicitation of public comments on biosimilars included in the proposed rule “Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2018 [Docket No. CMS-1676-P]” as published in the Federal Register on July 21, 2017.
AMCP joins a coalition of over 35 health care stakeholders committed to aligning 42 CFR part 2 (part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
